Enzo Biochem Azione

Enzo Biochem Conversione FCF

Delisted·17 apr 2025

Il Tasso di Conversione FCF (FCF/EBITDA) di Enzo Biochem (ENZ) al 14 ago 2026 è 335,05 %. L'anno precedente, Tasso di Conversione FCF (FCF/EBITDA) era 152,37 % — una variazione del 119,89% (superiore).

Conversione FCF

335,05 %

YoY

119,89%

Ultimo aggiornamento:

Tasso di Conversione FCF (FCF/EBITDA) di Enzo Biochem ammonta a 2026 335,05 % . Tasso di Conversione FCF (FCF/EBITDA) di Enzo Biochem ammontava a 2025 152,37 % . Diminuisce del 119,89% superiore rispetto all'anno precedente.
Access this data via the Eulerpool API

Enzo Biochem Analisi delle Azioni

Cosa fa Enzo Biochem? Enzo Biochem Inc is a US-based company operating in the biotechnology sector. It was founded in 1976 by Elazar Rabbani and is headquartered in New York. The company focuses on developing, producing, and marketing innovative diagnostic and therapeutic products for the medical industry. Enzo Biochem Inc's business model is based on the application of modern technologies for the development and synthesis of molecules for medical technology and life sciences. At the same time, the company also offers diagnostic testing systems and clinical laboratory services to its customers. Enzo Biochem's business model is therefore diverse and covers various areas. Enzo Biochem divides its business into three main segments: life sciences, clinical labs, and therapeutics. In the life sciences segment, the company engages in research and development of technologies for synthesizing molecules for medical technology. In the clinical labs segment, Enzo Biochem offers diagnostic testing systems and clinical laboratory services for use in medical diagnostics. The therapeutics segment manufactures therapeutic products for the treatment of viral infections. Enzo Biochem's product offering includes a wide range of products and services. This includes molecules for medical technology, diagnostic testing systems, and therapy products for viral infections. The product lines of Enzo Biochem include: - Molecules for medical technology: Enzo Biochem has developed a wide range of molecules for medical technology and is a leader in this field. These molecules include proteins, antibodies, and other biomolecules. The company also offers custom molecules for specific applications. - Diagnostic testing systems: The company offers a wide range of diagnostic testing systems tailored to the needs of laboratories and clinics. The tests include tests for infectious diseases, cancer, metabolic disorders, and other diseases. - Clinical laboratory services: Enzo Biochem provides a wide range of clinical laboratory services, including blood tests, microbiological tests, urine, stool, and body fluid tests, as well as histological analysis of tissue samples. - Therapy products: Enzo Biochem has developed a broad portfolio of therapy products for the treatment of viral infections. These products include immunomodulators, antivirals, and other therapeutics aimed at combating various pathogens. Enzo Biochem has made a name for itself in the biotechnology industry through continuous innovation and high-quality products. The company has also engaged in partnerships, acquisitions, and joint ventures to expand its global footprint. It has a global presence and works with leading pharmaceutical and biotech companies from around the world. Overall, Enzo Biochem has established itself as a leading biotechnology company operating in the fields of life sciences, clinical labs, and therapeutics. The company offers a wide range of products and services tailored to the needs of laboratories and clinics. Enzo Biochem has established itself as an innovation leader in the biotechnology industry and is committed to further expanding its business through the development of new products and technologies. Enzo Biochem è una delle aziende più popolari su Eulerpool.com.

Domande frequenti su Enzo Biochem azioni

Tasso di Conversione FCF (FCF/EBITDA) di Enzo Biochem è 335,05 % nel 2026.

Il Tasso di Conversione FCF (FCF/EBITDA) di Enzo Biochem è passato da 152,37 % a 335,05 %, con una variazione del 119,89 %. Il valore è superiore rispetto all'anno precedente.

Su Eulerpool è possibile consultare lo sviluppo storico completo del Enzo Biochem di Tasso di Conversione FCF (FCF/EBITDA) dal 2006, con valori annuali, grafici e analisi dettagliate.

La conversione FCF misura l'efficacia con cui l'EBITDA si converte in flusso di cassa libero. Una conversione più elevata indica un'efficiente allocazione di capitale e bassi costi di manutenzione.

Un 'buono' varia a seconda del settore e della fase di sviluppo dell'azienda. Su Eulerpool puoi confrontare Enzo Biochem di Tasso di Conversione FCF (FCF/EBITDA) con i competitor del settore e la media industriale per valutare se è attraente.

Per valutare di Tasso di Conversione FCF (FCF/EBITDA), è essenziale confrontarlo con i competitor nello stesso settore e industria. Su Eulerpool puoi trovare confronti diretti con l'industria per Tasso di Conversione FCF (FCF/EBITDA).

Access this data via the Eulerpool API

Flussi di cassa — Enzo Biochem

Tutte le Metriche Finanziarie — Enzo Biochem